Pancreatic Cancer Clinical Trials
Pancreatic cancer clinical trials provide patients with access to promising new cancer treatments that aren’t yet readily available. Additionally, because clinical trials provide a reliable way to evaluate the effectiveness of newly discovered drugs and techniques in relation to those that are currently being used, they play a pivotal role in facilitating advances in the prevention and cure of cancer.
Of course, the health, safety and care of clinical trial participants always come first. Before any patients are enrolled in a trial, thorough investigations are conducted to ensure safety. Clinical research is a very exciting and important part of medicine. In fact, even today’s most widely recommended treatments for pancreatic cancer were once available to patients only through clinical trials.
Florida's Cancer Center of Excellence
Moffitt is a Cancer Center of Excellence by the state of Florida. The designation recognizes providers that exceed service standards and excel in providing quality, comprehensive and patient-coordinated care.
Moffitt Cancer Center is nationally recognized for its extensive research efforts and clinical trials, which have resulted in landmark advances in all aspects of cancer care. For instance, through our robust pancreatic cancer clinical trials program, Moffitt patients can be among the first to take advantage of promising new:
- Risk assessments
- Prevention, detection and diagnostic methods
- Chemotherapy drugs
- Surgical techniques
- Radiation therapy delivery techniques, immunotherapies, molecular therapies and other innovative treatment options
As the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, Moffitt is a well-established leader in cancer research. We have a multispecialty team of pancreatic cancer experts who work together to ensure that each patient receives the most appropriate and beneficial care. Depending on a patient’s individual circumstances, this might include a clinical trial or another advanced treatment option.
To learn more about the pancreatic cancer clinical trials available at Moffitt Cancer Center, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. Our clinical trial navigators can help you find out if a trial is right for you, and no referrals are necessary.
Helpful Links:
-
Clinical Trials
CLINICAL TRIAL 20105
Using Radiogenomics to Noninvasively Predict the Malignant Potential of Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas and Uncover Hidden Biology
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 20788
An Advanced MRI Abdomen Protocol to Evaluate Pancreatic Ductal Adenocarcinoma in Surgically Resectable and Borderline Resectable Disease for Loco-Regional Heterogeneity and To Evaluate Treatment Response Status Post Surgery and MRI-GRT
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 21589
BASECAMP-1: An Observational Study Obtaining Solid Tumor Tissue from Subjects with Primary Surgical Resection and Leukapheresis for CAR T-Cell Therapy Manufacturing
Condition: Immunotherapy
Intervention:
CLINICAL TRIAL 21899
Phase Ib Expansion Study of CX-5461 in Patients with Solid Tumours and BRCA2 and/or PALB2 Mutation
Condition: Multiple
Intervention: CX-5461 ()
CLINICAL TRIAL 21908
A Systematic Review of Supplements Applicable in Treatment of Pancreatic Adenocarcinoma with Action on the mTOR Complex
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 22002
A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS
Condition: Multiple
Intervention: RMC-6236 ()
CLINICAL TRIAL 22139
Confocal Laser Endomicroscopy as an IMaging Biomarker (CLIMB study) for the Diagnosis of Pancreatic Cystic Lesions
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 22476
Support through remote observation and nutrition guidance program for individuals with pancreatic cancer undergoing surgery (STRONG-PCS)
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 22685
Phase 1/1B, Multicenter, Open-Label, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors
Condition: Multiple
Intervention: RMC-6236 (); RMC-9805 ()
CLINICAL TRIAL 23088
Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer: A Randomized Pilot Study
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 23448
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients with Solid Tumors with KRASG12D Mutation
Condition: Multiple
Intervention: Cemiplimab (); Cetuximab (); Erbitux (Cetuximab); Pembrolizumab (Keytruda); QTX3034 (); REGN2810 (Cemiplimab); mFOLFOX6 ()
CLINICAL TRIAL 23462
Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center (PANTHER-PIC)
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 23480
A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations
Condition: Multiple
Intervention: CGT4859 ()
CLINICAL TRIAL 23599
Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects with Advanced KRAS Mutant Cancers
Condition: Multiple
Intervention: Alimta (Pemetrexed); BBO-11818 (); Cetuximab (); Erbitux (Cetuximab); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); carboplatin (); cisplatin ()
CLINICAL TRIAL 23659
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Condition: Multiple
Intervention: ARV-806 ()
CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Olomorasib (); Sotorasib (); Trametinib (); VVD-159642 ()
CLINICAL TRIAL 23713
A Phase 2/3, Multicenter, Randomized Open-Label study of Zanzalintinib vs Everolimus in Participants with Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
Condition: Gastrointestinal Tumor
Intervention: Zanubrutinib (); Zanzalintinib (); everolimus (RAD001)
Treatment